A John Camm, Jonathan P Piccini, Marco Alings, Paul Dorian, Gilbert Gosselin, Marie-Claude Guertin, James E Ip, Peter R Kowey, Blandine Mondésert, Fransisco J Prins, Jean-Francois Roux, Bruce S Stambler, J W Martijn van Eck, Nadea Al Windy, Nathalie Thermil, Silvia Shardonofsky, David B Bharucha, Denis Roy
Background: Despite chronic therapies, atrial fibrillation (AF) leads to rapid ventricular rates (RVR) often requiring intravenous treatments. Etripamil is a fast-acting, calcium-channel blocker administered intranasally affecting the atrioventricular-node within minutes. Methods: ReVeRA evaluated efficacy and safety of etripamil for the reduction of ventricular rate (VR) in patients presenting urgently with AF-RVR (VR ≥110 bpm), was randomized, double-blind, placebo-controlled, and conducted in Canada and Netherlands...
November 11, 2023: Circulation. Arrhythmia and Electrophysiology